Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Monday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Corbus Pharmaceuticals (CRBP) shares fell 6.61% to $9.04 on Monday, underperforming competitors like Vanda and Viking Therapeutics during a broader market decline. The drop ended a four-day winning streak, with the stock trading 56% below its 52-week high. Trading volume was notably lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) slid 6.61% to $9.04 Monday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 1.55% to 25,873.18 and Dow Jones Industrial Average falling 0.26% to 52,498.64.
The stock's fall snapped a four-day winning streak.
Corbus Pharmaceuticals Holdings Inc. closed 56.03% below its 52-week high of $20.56, which the company achieved on October 20th.
The stock underperformed when compared to some of its competitors Monday, as Vanda Pharmaceuticals Inc. (VNDA) fell 3.85% to $6.00, Fortress Biotech Inc. (FBIO) remained unchanged, and Viking Therapeutics Inc. (VKTX) fell 1.90% to $38.12.
Trading volume (362,753) remained 188,167 below its 50-day average volume of 550,920.
Data source: Dow Jones Market Data, FactSet. Data compiled July 13, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-13-26 1721ET